


# Investment in heart health has declined for decades


**Cardiovascular disease (CVD) is the leading cause of death worldwide – more than cancer, diabetes and chronic respiratory diseases combined<sup>1-4</sup>**



While over **27%** of deaths globally are due to heart attack and stroke<sup>5</sup>...


...cardiovascular treatments comprised **3%** of all new drug launches in Europe and the US in the last five years<sup>6-15</sup>.

Between 2018 and 2022, nearly **10 times** more drugs were approved for cancer than for CVD, and **4 times** more for neurological conditions<sup>6-10</sup>.




The same trend was observed for EMA approvals<sup>11-15</sup>.

**Over the past few decades, the number of newly approved drugs for CVD has decreased significantly<sup>16</sup>**



## Factors that explain the reduction in investment in cardiovascular therapies over time<sup>16</sup>



**Large and long-term trials** needed to demonstrate improvement in cardiovascular health



**Small proportion** of cardiovascular drugs are going through **expedited regulatory pathways** (compared to oncology)



**Slow adoption** of new drugs into clinical practice and guidelines

### References

<sup>1</sup> Global Health Metrics. [http://www.healthdata.org/results/gbd\\_summaries?2019cardiovascular-diseases-level-2-cause](http://www.healthdata.org/results/gbd_summaries?2019cardiovascular-diseases-level-2-cause). Accessed June 9, 2023.  
<sup>2</sup> Global Health Metrics. [http://www.healthdata.org/sites/default/files/disease\\_and\\_injury/gbd\\_2019/topic\\_pdf/cause/1029.pdf](http://www.healthdata.org/sites/default/files/disease_and_injury/gbd_2019/topic_pdf/cause/1029.pdf). Accessed June 9, 2023.  
<sup>3</sup> Global Health Metrics. [http://www.healthdata.org/results/gbd\\_summaries/2019/chronic-respiratory-diseases-level-2-cause](http://www.healthdata.org/results/gbd_summaries/2019/chronic-respiratory-diseases-level-2-cause). Accessed June 9, 2023.  
<sup>4</sup> Global Health Metrics. [http://www.healthdata.org/results/gbd\\_summaries/2019/diabetes-mellitus-level-3-cause](http://www.healthdata.org/results/gbd_summaries/2019/diabetes-mellitus-level-3-cause). Accessed June 9, 2023.  
<sup>5</sup> World Health Organization (WHO). The top 10 causes of death. December 20, 2020. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Accessed June 9, 2023.  
<sup>6</sup> Mullard A. 2022 FDA approvals. *Nat Rev Drug Discov.* 2023;22(2):83-88.  
<sup>7</sup> Mullard A. 2021 FDA approvals. *Nat Rev Drug Discov.* 2022;21(2):83-88.  
<sup>8</sup> Mullard A. 2020 FDA drug approvals. *Nat Rev Drug Discov.* 2021;20(2):85-90.  
<sup>9</sup> Mullard A. 2019 FDA drug approvals. *Nat Rev Drug Discov.* 2020;19(2):79-84.  
<sup>10</sup> Mullard A. 2018 FDA drug approvals. *Nat Rev Drug Discov.* 2019;18(2):85-89.  
<sup>11</sup> European Medicines Agency (EMA). Human Medicines: highlights of 2022. [https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2022\\_en.pdf](https://www.ema.europa.eu/en/documents/report/human-medicines-highlights-2022_en.pdf). Accessed June 9, 2023.  
<sup>12</sup> European Medicines Agency (EMA). Human medicines: highlights of 2021. <https://www.ema.europa.eu/en/news/human-medicines-highlights-2021>. Accessed June 9, 2023.  
<sup>13</sup> European Medicines Agency (EMA). Human medicines: highlights of 2020. <https://www.ema.europa.eu/en/news/human-medicines-highlights-2020>. Accessed June 9, 2023.  
<sup>14</sup> European Medicines Agency (EMA). Human medicines: highlights of 2019. <https://www.ema.europa.eu/en/news/human-medicines-highlights-2019>. Accessed June 9, 2023.  
<sup>15</sup> European Medicines Agency (EMA). Human medicines: highlights of 2018. <https://www.ema.europa.eu/en/news/human-medicines-highlights-2018>. Accessed June 9, 2023.  
<sup>16</sup> Khakoo AY, Yurgin NR, Eisenberg PR, Fonarow GC. Overcoming Barriers to Development of Novel Therapies for Cardiovascular Disease: Insights From the Oncology Drug Development Experience. *JACC Basic Transl Sci.* 2019;4(2):269-274.